Your Best Stock

Takeda Pharmaceutical TAK

US equityMarket cap rank #271Infectious Disease
$18.57
−$0.24 (-1.28%)
Market open · Sep 24, 1:10 pm ET
After hours $18.81 0.00%
Open$18.55
Prev close$18.81
Day range$18.51 – $18.74
Volume1.59M
Market cap$59.30B
P/E (TTM)
Dividend yield3.22%

Fundamentals

Latest reported quarter: Q1, ended Jun 2026 · reported in JPY

Revenue¥1.22T+10.2% YoY
Operating profit¥201.42B+9.1% YoY
Net profit¥113.26B-8.9% YoY
Diluted EPS¥35.27-9.8% YoY
Free cash flow¥127.60M-40.8% YoY
Operating cash flow¥127.60M

Revenue, last 8 quarters

¥1.2TSep '24¥1.1TDec '24¥1.1TMar '25¥1.1TJun '25¥1.1TSep '25¥1.2TDec '25¥1.1TMar '26¥1.2TJun '26

Net profit, last 8 quarters

¥92.1BSep '24¥23.8BDec '24¥-103.1BMar '25¥124.3BJun '25¥-11.7BSep '25¥103.7BDec '25¥-368.4BMar '26¥113.3BJun '26

Diluted EPS by quarter

28.59Sep '247.29Dec '24-32.68Mar '2539.12Jun '25-3.92Sep '2532.34Dec '25-117.03Mar '2635.27Jun '26

Free cash flow by quarter

¥204.2BSep '24¥327.1BDec '24¥129.4BMar '25¥215.4MJun '25¥465.5BSep '25¥150.9BDec '25¥10.1BMar '26¥127.6MJun '26

Annual revenue

¥3.2TFY21¥3.6TFY22¥4.0TFY23¥4.3TFY24¥4.6TFY25¥4.5TFY26

Profitability & balance sheet

Gross margin65.5%
Operating margin10.4%
Net margin-3.5%
Return on equity-2.3%
Return on assets-1.1%
Return on invested capital-0.7%
Current ratio1.14
Liabilities / assets51.7%
Cash & investments¥527.58B
Total debt¥4.94T
Net cash (debt)-¥4.41T
Free cash flow / sales13.6%

Where the revenue comes from

Quarter 2027/Q1

By business line

  • Gastroenterology (GI)¥386.10B 31.7%
  • Plasma Derived Therapies (PDT)¥283.90B 23.3%
  • Rare Diseases¥206.00B 16.9%
  • Oncology¥165.60B 13.6%
  • Neuroscience¥113.60B 9.3%
  • Other¥50.70B 4.2%
  • Vaccines¥14.00B 1.1%

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
2026 Q2
(JPY)
Total Revenue as Reported ¥1.22T ¥4.51T ¥1.09T ¥1.19T ¥1.11T
Total Operating Revenue ¥1.22T ¥4.51T ¥1.09T ¥1.19T ¥1.11T
Cost of Revenue ¥406.68B ¥1.57T ¥405.70B ¥401.15B ¥380.06B
Gross Profit ¥813.22B ¥2.93T ¥688.84B ¥790.55B ¥732.74B
Operating Expense ¥611.81B ¥2.47T ¥646.77B ¥621.73B ¥663.74B
Selling and Admin Expenses ¥286.51B ¥1.08T ¥292.00B ¥282.78B ¥253.55B
Research & Development ¥167.40B ¥675.92B ¥195.32B ¥175.23B ¥161.48B
Depreciation & Amortization & Depletion ¥110.93B ¥633.54B ¥154.84B ¥141.91B ¥205.16B
-Depreciation & Amortization ¥110.93B ¥633.54B ¥154.84B ¥141.91B ¥205.16B
Other Operating Expenses ¥46.97B ¥76.00B ¥4.62B ¥21.80B ¥43.55B
Operating Profit ¥201.42B ¥464.45B ¥42.07B ¥168.82B ¥69.00B
Net Non-Operating Interest Income (Expense) -¥39.24B -¥143.77B -¥35.88B -¥35.76B -¥38.74B
Non-Operating Interest Income ¥24.61B ¥16.88B -¥189.15B ¥87.87B ¥44.40B
Non-Operating Interest Expense ¥63.85B ¥148.12B -¥165.80B ¥123.63B ¥83.14B
Other Income (Expense) ¥538.00M -¥463.03B -¥461.22B ¥799.00M -¥2.08B
Earnings from Equity Interest ¥538.00M -¥2.18B -¥361.00M ¥799.00M -¥2.08B
Pretax Profit ¥162.72B -¥142.36B -¥455.02B ¥133.86B ¥28.17B
Tax ¥49.46B ¥9.77B -¥86.62B ¥30.13B ¥39.90B
Net Profit ¥113.26B -¥152.13B -¥368.41B ¥103.73B -¥11.73B
Profit from Continuing Operations ¥113.26B -¥152.13B -¥368.41B ¥103.73B -¥11.73B
Minority Interests ¥60.00M ¥264.00M ¥62.00M ¥94.00M ¥72.00M
Net Income to Parent Company ¥113.20B -¥152.39B -¥368.47B ¥103.64B -¥11.80B
Net Income to Common Stockholders ¥113.20B -¥152.39B -¥368.47B ¥103.64B -¥11.80B
Basic EPS ¥35.83 -¥48.38 -¥117.03 ¥32.87 -¥3.92
Diluted EPS ¥35.27 -¥48.38 -¥117.03 ¥32.34 -¥3.92
Dividend Per Share ¥0.00 ¥97.15 ¥49.28 ¥0.00 ¥47.87
Total Other Finance Costs ¥12.53B
Gain on Sale of Security ¥6.14B
Special Income (Charges) -¥466.99B
-Less:Restructuring and Mergern & Acquisition ¥71.82B
-Less:Other Special Charges ¥412.23B
-Less:Write Off ¥1.36B
-Gain on Sale Of Business ¥18.27B
-Gain on Sale of Property/Plant/Equipment ¥165.00M

Balance sheet

Line item 2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
2026 Q2
(JPY)
Total Assets ¥15.66T ¥15.51T ¥15.51T ¥15.41T ¥14.47T
Total Current Assets ¥3.15T ¥3.09T ¥3.09T ¥3.12T ¥2.92T
Cash and Cash Equivalents & Short-Term Investments ¥527.58B ¥636.94B ¥636.94B ¥761.94B ¥739.68B
-Cash and Cash Equivalents ¥460.98B ¥595.05B ¥595.05B ¥654.94B ¥681.49B
-Short Term Investments ¥66.60B ¥41.89B ¥41.89B ¥107.00B ¥58.19B
Receivables ¥956.14B ¥876.35B ¥876.35B ¥757.92B ¥702.24B
-Accounts Receivable ¥930.38B ¥977.36B ¥977.36B ¥736.46B ¥688.96B
-Taxes Receivable ¥25.76B ¥32.04B ¥32.04B ¥21.46B ¥13.28B
Inventory ¥1.45T ¥1.40T ¥1.40T ¥1.41T ¥1.30T
Other Current Assets ¥188.78B ¥162.64B ¥162.64B ¥175.78B ¥166.39B
Total Non-Current Assets ¥12.51T ¥12.42T ¥12.42T ¥12.29T ¥11.55T
Net PPE ¥2.14T ¥2.12T ¥2.12T ¥2.08T ¥1.98T
Investments and Advances ¥473.22B ¥448.74B ¥448.74B ¥434.17B ¥374.33B
-Available for Sale Securities ¥463.14B ¥439.94B ¥439.94B ¥423.98B ¥365.41B
-Long Term Equity Investment ¥10.08B ¥8.80B ¥8.80B ¥10.19B ¥8.92B
Goodwill and Other Intangible Assets ¥9.28T ¥9.23T ¥9.23T ¥9.27T ¥8.73T
-Goodwill ¥5.89T ¥5.81T ¥5.81T ¥5.75T ¥5.43T
-Other Intangible Assets ¥3.39T ¥3.42T ¥3.42T ¥3.52T ¥3.30T
Non-Current Deferred Assets ¥539.15B ¥546.26B ¥546.26B ¥427.49B ¥389.77B
Other Non-Current Assets ¥80.30B ¥77.01B ¥77.01B ¥77.80B ¥70.53B
Total Liabilities ¥8.10T ¥8.08T ¥8.08T ¥7.76T ¥7.34T
Total Current Liabilities ¥2.76T ¥2.83T ¥2.83T ¥2.61T ¥2.14T
Payables ¥564.72B ¥589.23B ¥589.23B ¥615.93B ¥561.89B
-Accounts Payable ¥446.78B ¥324.37B ¥324.37B ¥467.59B ¥438.99B
-Total Tax Payable ¥117.93B ¥97.88B ¥97.88B ¥148.34B ¥122.91B
Short-Term Debt and Capital Lease Obligation ¥519.97B ¥512.16B ¥512.16B ¥583.15B ¥293.86B
-Current Debt ¥519.97B ¥512.16B ¥512.16B ¥583.15B ¥293.86B
Current Provisions ¥995.05B ¥998.50B ¥998.50B ¥572.13B ¥551.52B
Other Current Liabilities ¥684.81B ¥732.19B ¥732.19B ¥838.98B ¥732.38B
Total Non-Current Liabilities ¥5.34T ¥5.25T ¥5.25T ¥5.15T ¥5.20T
Long Term Debt and Capital Lease Obligation ¥4.42T ¥4.37T ¥4.37T ¥4.27T ¥4.35T
-Long Term Debt ¥4.42T ¥4.37T ¥4.37T ¥4.27T ¥4.35T
Non-Current Liabilities ¥37.93B ¥37.55B ¥37.55B ¥34.06B ¥32.77B
Non-Current Deferred Liabilities ¥27.04B ¥26.80B ¥26.80B ¥31.28B ¥33.03B
Employee Benefits ¥141.79B ¥143.68B ¥143.68B ¥150.60B ¥144.10B
Other Non-Current Liabilities ¥713.09B ¥671.07B ¥671.07B ¥665.12B ¥635.29B
Total Equity ¥7.56T ¥7.43T ¥7.43T ¥7.64T ¥7.13T
Stockholders' Equity ¥7.56T ¥7.43T ¥7.43T ¥7.64T ¥7.13T
Capital Stock ¥1.70T ¥1.70T ¥1.70T ¥1.69T ¥1.69T
-Common Stock ¥1.70T ¥1.70T ¥1.70T ¥1.69T ¥1.69T
Additional Paid-In Capital ¥1.79T ¥1.78T ¥1.78T ¥1.75T ¥1.73T
Retained Earnings ¥667.01B ¥712.38B ¥712.38B ¥1.10T ¥1.15T
Less: Treasury Stock ¥47.44B ¥49.13B ¥49.13B ¥49.12B ¥49.12B
Gains/Losses Not Affecting Retained Earnings -¥11.06B -¥2.85B -¥2.85B -¥2.94B -¥3.60B
Other Equity Interests ¥3.46T ¥3.30T ¥3.30T ¥3.15T ¥2.61T
Minority Interests ¥989.00M ¥1.21B ¥1.21B ¥1.15B ¥992.00M
-Other Receivables ¥36.29B ¥36.29B
-Receivables Adjustments Allowances -¥169.33B -¥169.33B
-Gross PPE ¥3.65T ¥3.65T
-Accumulated Depreciation -¥1.53T -¥1.53T
-Other Payable ¥166.98B ¥166.98B
Long Term Accounts Payable and Other Payables ¥3.27B ¥2.31B

Cash flow

Line item 2027 Q1
(JPY)
2026 ANNUAL
(JPY)
2026 Q4
(JPY)
2026 Q3
(JPY)
2026 Q2
(JPY)
Operating Cash Flow ¥127.60M ¥1.04T ¥74.53B ¥373.25B ¥593.44B
Net cash flow from investing -¥87.70M -¥369.14B -¥58.02B -¥229.80B -¥81.29B
Financing Cash Flow -¥180.30M -¥496.82B -¥77.49B -¥192.45B -¥226.67B
Ending Cash Balance ¥461.00M ¥595.05B ¥595.05B ¥654.94B ¥681.49B
Net Change in Cash -¥140.50M ¥175.47B -¥60.98B -¥48.99B ¥285.48B
Beginning Cash Balance ¥595.10M ¥385.11B ¥654.94B ¥681.49B ¥350.00M
Effect of Exchange Rate Changes ¥6.40M ¥34.47B ¥1.10B ¥22.44B ¥10.93B
Free Cash Flow ¥127.60M ¥626.77B ¥10.14B ¥150.88B ¥465.54B
Net cash flow from continuing operations ¥1.04T ¥74.53B ¥373.25B ¥378.23B
Net Income from Continuing Operations -¥152.13B -¥368.41B ¥103.73B -¥11.73B
Gain/Loss from Continuing Operations ¥116.71B ¥131.55B -¥441.00M ¥2.38B
Depreciation & Depletion & Amortization ¥721.13B ¥163.87B ¥190.64B ¥184.98B
Deferred Tax ¥9.77B -¥86.62B ¥30.13B ¥39.90B
Other Non-Cash Items ¥99.11B -¥23.33B ¥85.09B ¥90.37B
Change in Working Capital ¥199.91B ¥251.00B -¥39.33B ¥21.94B
-Change in Receivables -¥70.17B -¥97.52B -¥10.94B -¥9.80B
-Change in Inventory -¥61.29B ¥18.70B -¥37.96B -¥28.96B
-Change in Payables and Accrued Expense -¥3.15B ¥4.80B ¥3.29B ¥16.54B
-Change in Other Current Liabilities -¥81.61B -¥96.37B ¥20.07B ¥12.22B
-Change In Other Working Capital ¥416.12B ¥421.38B -¥13.79B ¥31.94B
Net Cash Flow from Continuing Investing Activities -¥369.14B -¥58.02B -¥229.80B -¥48.13B
Net PPE Purchase and Sale -¥169.55B -¥46.31B -¥41.62B -¥40.10B
Net Intangibles Purchase and Sale -¥238.66B -¥18.03B -¥180.74B -¥12.73B
Net Business Purchase and Sale ¥33.58B ¥515.00M ¥3.36B ¥417.00M
Net Investment Purchase and Sale -¥10.40B ¥723.00M -¥13.37B ¥1.33B
Net Other Investing Changes -¥2.78B -¥51.00M -¥2.64B -¥267.00M
Net Cash Flow from Continuing Financing Activities -¥496.82B -¥77.49B -¥192.45B -¥11.98B
Net Issuance Payments Of Debt ¥1.08B -¥25.62B -¥9.89B ¥36.56B
Net Common Stock Issuance -¥51.60B ¥0.00 ¥0.00 ¥0.00
Cash Dividends Paid -¥311.90B -¥8.79B -¥149.03B -¥8.79B
Net Other Financing Charges -¥13.01B -¥3.79B -¥3.74B -¥4.15B
Scroll to Top